Glenmark Pharmaceuticals FY24 Annual Earnings Summary

Monroe facility received a warning letter, potentially delaying injectable product approvals and US growth acceleration.

US business remains a big unknown due to pricing erosion (~5% mid-single digit) and supply disruptions; management struggles to provide specific guidance.

Monroe plant is awaiting FDA inspection; any delay in approval or commercialization could impact injectable revenue and margin improvement.

Remediation completed but FDA reinspection pending; delay could impact injectable commercialization timeline.

North America revenue fell 12.4% YoY; recovery depends on generic Flovent approval and scale-up of recent launches.

Slowdown in acute segments like respiratory and anti-infectives may pressure India growth, which is guided to single digits.

Net debt at INR 2,947 crore and interest costs doubled YoY due to higher LIBOR, impacting profitability.

Monroe facility remediation is largely complete, but FDA reinspection timeline is unpredictable, delaying potential revenue from the plant.

The GLS divestment to Nirma is subject to regulatory and shareholder approvals; any delay could impact FY25 margin and PAT improvement plans.

Generic Flovent pMDI NDA filing expected in Q1 FY25, but approval and launch timing remain uncertain, affecting U.S. growth trajectory.

Despite guidance of INR 1,000 crore quarterly run rate, the one-time restructuring impact may have lingering effects on channel dynamics.

Cash payout of ~INR 300 crore in FY25 for DOJ and Zetia settlements, impacting free cash flow.